Anti-ctla-4 binding proteins and methods of use thereof
AssigneeGigaGen, Inc.
InventorsDavid Scott JOHNSON, Adam Shultz ADLER, Rena Aviva MIZRAHI, Yoong Wearn LIM, Michael ASENSIO, Erica Lyn STONE
Life of this patent
Estimating the term…
Abstract
Provided herein are antigen-binding proteins (ABPs) that selectively bind to CTLA-4 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
Claims198
An isolated antigen binding protein (ABP) that specifically binds a human cytotoxic T-lymphocyte associated protein 4 (CTLA-4), wherein
- the ABP contacts amino acids K130, Y139, L141, I143 but does not contact amino acid R70 of the CTLA-4;
- and/or
- the CTLA-4 can associate with CD80/CD86 when bound to the ABP;
- and/or
- an interaction between the ABP and amino acid L74A and/or E68 of the CTLA-4 is greater than an interaction between Ipilimumab and amino acid L74A of CTLA-4.
An isolated antigen binding protein (ABP) that specifically binds a human cytotoxic T-lymphocyte associated protein 4 (CTLA-4), wherein the ABP comprises:
- (a) a CDR1-L consisting of SEQ ID NO:12078, a CDR2-L consisting of SEQ ID NO:12079, a CDR3-L consisting of SEQ ID NO:
- 12080, a CDR1-H consisting of SEQ ID NO:12075, a CDR2-H consisting of SEQ ID NO:12076 and a CDR3-H consisting of SEQ ID NO:12077;
- (b) a CDR1-L consisting of SEQ ID NO:
- 1014, a CDR2-L consisting of SEQ ID NO:
- 2014, a CDR3-L consisting of SEQ ID NO:
- 3014, a CDR1-H consisting of SEQ ID NO:
- 4014, a CDR2-H consisting of SEQ ID NO:
- 5014 and a CDR3-H consisting of SEQ ID NO:
- 6014;
- (c) a CDR1-L consisting of SEQ ID NO:
- 12004, a CDR2-L consisting of SEQ ID NO:
- 12014, a CDR3-L consisting of SEQ ID NO:
- 12024, a CDR1-H consisting of SEQ ID NO:
- 12039, a CDR2-H consisting of SEQ ID NO:
- 12049, and a CDR3-H consisting of SEQ ID NO:
- 12059;
- (d) a CDR1-L consisting of SEQ ID NO:
- 12005, a CDR2-L consisting of SEQ ID NO:
- 12015, a CDR3-L consisting of SEQ ID NO:
- 12025, a CDR1-H consisting of SEQ ID NO:
- 12040, a CDR2-H consisting of SEQ ID NO:
- 12050, and a CDR3-H consisting of SEQ ID NO:
- 12060;
- (e) a CDR1-L consisting of SEQ ID NO:
- 12006, a CDR2-L consisting of SEQ ID NO:
- 12016, a CDR3-L consisting of SEQ ID NO:
- 12026, a CDR1-H consisting of SEQ ID NO:
- 12041, a CDR2-H consisting of SEQ ID NO:
- 12051, and a CDR3-H consisting of SEQ ID NO:
- 12061;
- (f) a CDR1-L consisting of SEQ ID NO:
- 12007, a CDR2-L consisting of SEQ ID NO:
- 12017, a CDR3-L consisting of SEQ ID NO:
- 12027, a CDR1-H consisting of SEQ ID NO:
- 12042, a CDR2-H consisting of SEQ ID NO:
- 12052, and a CDR3-H consisting of SEQ ID NO:
- 12062;
- or
- (g) a CDR1-L consisting of SEQ ID NO:
- 12008, a CDR2-L consisting of SEQ ID NO:
- 12018, a CDR3-L consisting of SEQ ID NO:
- 12028, a CDR1-H consisting of SEQ ID NO:
- 12043, a CDR2-H consisting of SEQ ID NO:
- 12053, and a CDR3-H consisting of SEQ ID NO:
- 12063.
An isolated antigen binding protein (ABP) that specifically binds an antigen, comprising an IGHG1*01 human heavy chain constant region gene segment, optionally wherein the antigen is a human cytotoxic T-lymphocyte associated protein 4 (CTLA-4).
A method of reducing CTLA-4HI Tregs in a subject with limited proliferation of remaining Tregs comprising administering to the subject an effective dose of an antigen binding protein (ABP) that specifically binds a human cytotoxic T-lymphocyte associated protein 4 (CTLA-4).
Dependencies are inferred from the claim text.